The Looming Success in Cancer Vaccination
Abstract
Cancer vaccination projects are on trial worldwide and the results are far-off being a remarkable success. Albeit, thousands of clinical trials are taking place, only a several of those are producing a significant result to increase the survival rate of the patients. Four vaccines (Human papillomavirus - HPV vaccines, Hepatitis B virus - HBV vaccines, Sipuleucel-T and Oncophage) are approved for market in the United States and Russia so far. Most of the prototype vaccines are yielding at phase III clinical trials after being successful at phase I and II. Apparently, new visions and approaches are required to guide these projects to harvest better results.
References
[2] Viewed 15 January 2018. https://www.cancer.gov/about-cancer/treatment/clinical-trials/search.
[3] Geresu MA, Sultan AF, Ahmed SK, et al. 2016, Immunotherapy against cancer: A comprehensive review, Journal of Cancer Research and Experimental Oncology, vol. 8(2): 15-25. doi:10.5897/JCREO2015.0124.
[4] Viewed 15 January 2018. https://www.cancer.gov/about-cancer/causes-prevention/vaccines-fact-sheet.
[5] Mellman I, Coukos G, Dranoff G, 2011, Cancer immunotherapy comes of age. Nature, vol. 480(7378): 480-489.
[6] Zappasodi R, de Braud F, Di Nicola M, 2015, Lymphoma immunotherapy: current status, Front. Immunol., vol. 1. doi:10.3389/fimmu.2015.00448
[7] Levy R, Ganjoo KN, Leonard JP, et al. 2014, Active Idiotypic Vaccination Versus Control Immunotherapy for Follicular Lymphoma, Journal of Clinical Oncology, vol. 32(17): 1797-1803. doi:10.1200/JCO.2012.43.9273.
[8] Wood C, Srivastava P, Bukowski R, et al. 2008, C-100-12 RCC study group an adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: A multicentre, open label, random-ised phase III trial, Lancet, vol. 372: 145-154.
[9] Testori A, Richards J, Whitman E, et al. 2008, C-100-21 study group phase III comparison of vitespen: An autologous tumor derived heat shock protein gp96 peptide complex vaccine with physician’s choice of treatment for stage IV melanoma, J. Clin. Oncol., vol. 26(6): 955-962.
[10] Hodi FS, O'Day SJ, McDermott DF, et al. 2010, Improved survival with ipilimumab in patients with metastatic melanoma, N. Engl. J. Med., vol. 363: 711-723.
[11] Drake CG, 2009, Immunotherapy for prostate cancer, J. Clin. Onco., vol. 27: 4035-4037.
[12] Kantoff PW, Schuetz TJ, Blumenstein BA, et al. 2010, Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castra-tion-resistant prostate cancer, J. Clin. Oncol., vol. 28: 1099-10105.
[13] Noh CIC and Rahman MS, 2008, Comparison effects of MT novel medium with modified DKW basal medium on walnut micropropagation, Proceeding book of the 1st national conference of student biology and modern world, pp. 204.
[14] Viewed 16 January 2018. https://www.clinicaltrials.gov/.
[15] Drakes ML and Stiff PJ, 2014, Harnessing immunosurveillance: current developments and future directions in cancer immunotherapy, ImmunoTargets and Therapy, 2014:3 151 – 165.
[16] Valle I, Tramalloni D, Bragazzi NL, 2015, Cancer prevention: state of the art and future prospects, J. Prev. Med. Hyg., vol. 56: 21-27.
[17] Walter S, Weinschenk T, Reinhardt C, et al. 2012. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival, Nature Medicine, vol. 18: 1254-61. doi:10.1038/nm.2883.
[18] Rini BI, Stenzl A, Zdrojowy R, et al. 2016, IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial, The Lancet Oncology, vol. 17(11): 1599-1611.
[19] Afroz S, Rahman SS, Hossain MM, 2017. A Study Survey on Risk Factors associated with Breast Cancer in Bangladeshi Population, Journal of Cancer Science & Therapy, vol. 9 (5): 463-7. doi:10.4172/1948-5956.1000460.
Copyright (c) 2018 Shafkat Shamim Rahman
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors submitting to USP journals agree to publish their manuscript under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0) where authors agree to allow third parties to share their work (copy, distribute, transmit) and to adapt it, under the condition that the authors are given credit, and that in the event of reuse or distribution, the terms of this license are made clear
Authors retain copyright of their work, with first publication rights (online and print) granted to Universe Scientific Publishing or the owner of the journal in question.
